BioCryst Pharmaceuticals
BCRX
BCRX
233 hedge funds and large institutions have $1.24B invested in BioCryst Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 101 increasing their positions, 57 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
233
Holders Change
-3
Holders Change %
-1.27%
% of All Funds
3.71%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
21
Increased
101
Reduced
57
Closed
22
Calls
$22.4M
Puts
$5.79M
Net Calls
+$16.6M
Net Calls Change
+$3.11M
Top Buyers
| 1 |
B
Braidwell
Stamford,
Connecticut
|
$38M |
| 2 |
DM
Deerfield Management
New York
|
$23.3M |
| 3 |
Nuveen Asset Management
Chicago,
Illinois
|
$18.2M |
| 4 |
BlackRock
New York
|
$119M |
| 5 |
Morgan Stanley
New York
|
$12.9M |
